Frye, Mark A. http://orcid.org/0000-0001-6997-4215
Nemeroff, Charles B. http://orcid.org/0000-0001-7867-1160
Article History
Received: 23 March 2023
Revised: 23 June 2023
Accepted: 11 July 2023
First Online: 7 August 2023
Competing interests
: <i>MAF, M.D. 2023</i>. Grant Support: Assurex Health, Mayo Foundation. Speakers’ Bureau: NONE. CME/Travel/Honoraria: Carnot Laboratories, American Physician Institute. Financial Interest/Stock ownership/Royalties: Chymia LLC. <i>CBN M.D., Ph.D</i>. Research/Grants: National Institutes of Health (NIH). Consulting: AbbVie, ANeuroTech (division of Anima BV), Signant Health, Magstim, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Sage, Silo Pharma, Engrail Therapeutics, Pasithea Therapeutic Corp., GoodCap Pharmaceuticals, Inc., Senseye, Clexio, Ninnion Therapeutics, EmbarkNeuro, SynapseBio, BioXcel Therapeutics, Relmada Therapeutics. Stockholder: Seattle Genetics, Antares, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, Naki Health, Relmada Therapeutics. Scientific Advisory Boards: ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Heading Health, Pasithea Therapeutic Corp., Sage. Board of Directors: Gratitude America, ADAA, Lucy Scientific Discovery, Inc. Patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1); Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). Speakers Bureau: None.